What question did this study set out to answer?

To review the technological developments and clinical feasibility of creating patient-tailored cancer vaccines directed against unique somatic tumor mutations.

March 22, 2018Science

Personalized vaccines for cancer immunotherapy

View Full Paper

Ask AI

Bookmark

Authors

UŞUğur ŞahinGoethe University Frankfurt ÖTÖzlem TüreciJohannes Gutenberg University Mainz

Discussion

Member takes

Implication

Clinical review demonstrates the feasibility and safety of personalized neoepitope vaccines in cancer patients, highlighting a viable path toward individualized immunotherapy.

Key Points

To review the technological developments and clinical feasibility of creating patient-tailored cancer vaccines directed against unique somatic tumor mutations.
Assessment of genomic sequencing and bioinformatics pipelines used to identify patient-specific somatic mutations and cancer neoepitopes.
Evaluation of preliminary first-in-human clinical trials investigating on-demand, customized neoepitope vaccine formulations.
Patient tumors harbor distinct somatic mutation profiles that generate unique neoepitopes recognizable as foreign targets by autologous T cells.
Early human clinical trials establish the feasibility, safety, and immunotherapeutic activity of vaccines engineered against individual mutational signatures.

Cite This Study

Şahin et al. (2018) studied this question.

synapsesocial.com/papers/69cfb6a7ca738d6973cde84c https://doi.org/10.1126/science.aar7112

View Full Paper

Ask AI

Bookmark

Implication

Clinical review demonstrates the feasibility and safety of personalized neoepitope vaccines in cancer patients, highlighting a viable path toward individualized immunotherapy.

Personalized vaccines for cancer immunotherapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Personalized vaccines for cancer immunotherapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider